12A-1071228
Enterovirus 71 (EV71 or EV-A71) is a globally emerging infectious virus. Infection with EV71 in children is associated with a wide range of disease severity, including encephalitis, tachycardia, cardiopulmonary failure, and sudden death. At present, there is no FDA-approved therapeutics for EV71. Early diagnosis for the severe EV71 infection in high-risk children is the key to successful patient care. We identified EV71 mutations associated with severe disease. Two examples for the embodiment of this invention: One is to perform RT-PCR amplification and sequencing for the mutations of virulence determinants. A second example is to perform ELISA or IFA for the VP1 protein epitope containing the mutated amino acid.
- Most existing literature identified EV71 adaptive mutations associated with disease severity in tissue culture cell lines or laboratory mice, rather than in human patients.
- Our invention is novel, based on data with statistical significance.
Diagnosis of high-risk patients with severe EV71 infection
Chia-Ho Shih
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Early Diagnosis of Severe EV71 Infection in High-risk Patients